AgomAb Therapeutics NV has reached a significant milestone by dosing its first patient in the global NOV-ERA Phase 2b study of ontunisertib, a drug aimed at treating Fibrostenosing Crohn's disease (FSCD). This event, reported on October 13, 2026, is crucial for the company as it continues to develop therapies for fibro-inflammatory diseases.
AgomAb, incorporated in Belgium, operates in the biological products sector, focusing on developing innovative therapies that target fibro-inflammation. The company trades under the ticker AGMB on the Nasdaq exchange. Recent filings show a consistent stream of activity, including the latest 6-K filing on October 13, 2026, which detailed this important clinical trial milestone.
The filing states, "On October 13, 2026, the Company issued a press release titled, 'Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease.'" This announcement highlights the commencement of a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of ontunisertib in approximately 320 patients.
The NOV-ERA study aims to assess the drug's effectiveness in treating FSCD, a condition characterized by progressive bowel damage and a significant burden on patients. Philippe Wiesel, Agomab's Chief Medical Officer, emphasized the importance of this study, stating, "Dosing the first patient in NOV-ERA marks the beginning of an exciting next chapter for our Company and for the late-stage development of ontunisertib." He noted that there are currently no approved therapies specifically addressing the fibrotic component of FSCD.
This clinical trial is not only significant for AgomAb but also for the broader industry, as it may influence the treatment landscape for fibro-inflammatory diseases. The successful development of ontunisertib could provide a much-needed option for patients suffering from FSCD, which has limited treatment options available.
Furthermore, the initiation of the NOV-ERA study triggers a €7 million milestone payment to the former shareholders of Origo Biopharma, following Agomab's acquisition of the company in 2021. This acquisition included potential milestone payments totaling up to €20 million, indicating the company's commitment to advancing its drug development pipeline.
The NOV-ERA study will evaluate three different dose levels of ontunisertib, with the primary endpoint being endoscopic passability at Week 24. This trial is expected to provide critical data that could support regulatory submissions in the future.
As AgomAb moves forward with this study, it will be essential to monitor its progress and any subsequent filings that may provide updates on the trial's outcomes. The filing does not specify what happens next, but the company has indicated its commitment to transparency and keeping stakeholders informed.